Tuberous Sclerosis Complex Pipeline

DelveInsight’s Tuberous Sclerosis Complex Pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects across the Tuberous Sclerosis Complex market. The disease summary and Tuberous Sclerosis Complex therapy guidelines are also included in a complete description of the Tuberous Sclerosis Complex pipeline environment.

Some Important Findings from the Tuberous Sclerosis Complex Pipeline Report

• Pipeline therapy for Tuberous Sclerosis Complex such as Pascomer is in the Phase II/III of clinical trials.

• Some pipeline therapies for Tuberous Sclerosis Complex including Ganaxolone, TAVT-18, and Basimglurant are in the Phase II of clinical trials.

• Key companies such as AFT Pharmaceuticals, Marinus Pharmaceuticals, Tavanta Therapeutics, Noema Pharma, among others are actively working towards the development of novel therapies for Tuberous Sclerosis Complex.

To learn more, request sample @ Tuberous Sclerosis Complex Pipeline Assessment

Tuberous Sclerosis Complex: Overview

Tuberous Sclerosis Complex is a hereditary condition that causes the creation of many non-cancerous (benign) tumors throughout the body. These tumors can develop in the skin, brain, kidneys, and other organs. Every day, at least two children are born with Tuberous Sclerosis Complex globally. 

Tuberous Sclerosis Complex: Symptoms

Tuberous Sclerosis is a disorder with a wide range of symptoms. Even within the same family, the signs, symptoms, and severity of the condition can differ considerably from one person to the next. Any organ system of the body can be affected.

Tuberous Sclerosis Complex: Treatment

Treatment may necessitate the collaborative efforts of a team of specialists. Pediatricians and general internists, neurologists, dermatologists, cardiologists, dental specialists, eye specialists, psychiatrists, and other healthcare professionals may be required to plan an affected child’s treatment systematically and comprehensively. Affected individuals and their families will benefit from genetic counselling.

Tuberous Sclerosis Complex Pipeline Analysis: Drug Profile

Ganaxolone: Marinus Pharmaceuticals

Product Description

Ganaxolone is a GABAA receptor modulator that influences brain activity. This process can include suppressing abnormal electrical discharges that cause seizures and status epilepticus, as well as restoring balance in disrupted neuronal activity in other CNS disorders.

Research and Development in the Tuberous Sclerosis Complex Pipeline Landscape

Phase II

NCT04285346: In April 2020, Marinus Pharmaceuticals began a Phase 2 open-label 12-week trial of adjunctive ganaxolone treatment (Part A) in Tuberous Sclerosis Complex-related epilepsy followed by long-term treatment (Part B) in Tuberous Sclerosis Complex-related epilepsy. This is an OL proof of concept research of supplemental GNX medication in patients with TSC and/or a mutation in either the TSC1 or TSC2 gene.

Tuberous Sclerosis Complex Pipeline Therapies and Key Companies

• Pascomer: AFT Pharmaceuticals

• Ganaxolone: Marinus Pharmaceuticals

• TAVT-18: Tavanta Therapeutics

• Basimglurant: Noema Pharma

Get more insights @ Tuberous Sclerosis Complex Pipeline Therapies

Tuberous Sclerosis Complex Therapeutics Assessment 

•  By Product Type

• Monotherapy

• Combination Therapy

• By Stage

• Discovery

• Pre-Clinical

• Phase I

• Phase II

• Phase III

• Pre-registration

• By Route of Administration

• Inhalation

• Intravenous

• Oral

• Subcutaneous

• By Molecule Type

• Small Molecule

• Stem Cell Therapy

• Gene Therapy

• Targets

• Immune System

• Multiple Kinase

• By Mechanism of Action

• Protease Inhibitors

• Immunomodulatory

Scope of the Report

Coverage: Global

Tuberous Sclerosis Complex Key Players: AFT Pharmaceuticals, Marinus Pharmaceuticals, Tavanta Therapeutics, Noema Pharma, among others

Tuberous Sclerosis Complex Pipeline Therapies: Pascomer, Ganaxolone, TAVT-18, Basimglurant, and others

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Key questions answered in the Tuberous Sclerosis Complex Pipeline Report

• What are the different types of Tuberous Sclerosis Complex treatments?

• How many firms are developing medicines for Tuberous Sclerosis Complex?

• Which of these firms’ pharmaceuticals is the most popular?

• In total, how many Tuberous Sclerosis Complex drugs has each firm produced?

• How many novel therapies for Tuberous Sclerosis Complex are in the early, mid, and late stages of development?

• How many of the medications in development can be used on their own or in conjunction with other therapies?

• What are the most significant industry-industry and industry-academy collaborations, mergers and acquisitions, and licensure practises that will have an impact on Tuberous Sclerosis Complex?

Related Reports

Central Precocious Puberty Pipeline Insights

Get comprehensive analysis of Central Precocious Puberty pipeline therapies and key companies including AstraZeneca, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/